APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dermatomycoses Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Dermatomycoses Drug Industry Research Report 2026

26 December 2025122 pages

Choose your research edition.

Industry ResearchDermatomycoses Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatomycoses Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Dermatomycoses Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatomycoses Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatomycoses Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Dermatomycoses Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Dermatomycoses Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Dermatomycoses Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Dermatomycoses Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Dermatomycoses Drug include Vyome Biosciences Pvt Ltd, Viamet Pharmaceuticals Inc, TGV-Laboratories, Sol-Gel Technologies Ltd, Novan Inc, Helix BioMedix Inc, Dermala Inc, Daewoong Pharmaceutical Co Ltd and Blueberry Therapeutics Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Dermatomycoses Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Dermatomycoses Drug Market by Company

Vyome Biosciences Pvt Ltd

Viamet Pharmaceuticals Inc

TGV-Laboratories

Sol-Gel Technologies Ltd

Novan Inc

Helix BioMedix Inc

Dermala Inc

Daewoong Pharmaceutical Co Ltd

Blueberry Therapeutics Ltd

Biolab Farmaceutica Ltda

Anacor Pharmaceuticals Inc

Dermatomycoses Drug Segment by Type

BB-2603

Dapaconazole

Clotrimazole

Others

Dermatomycoses Drug Segment by Application

Hospital

Clinic

Others

Dermatomycoses Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatomycoses Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatomycoses Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatomycoses Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Dermatomycoses Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Dermatomycoses Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Dermatomycoses Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Dermatomycoses Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Dermatomycoses Drug Sales (W Units) of Manufacturers (2021-2026) Table 7. Global Dermatomycoses Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Dermatomycoses Drug Revenue of Manufacturers (2021-2026) Table 9. Global Dermatomycoses Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Dermatomycoses Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Dermatomycoses Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Dermatomycoses Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Dermatomycoses Drug, Product Type & Application Table 14. Global Dermatomycoses Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Dermatomycoses Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Vyome Biosciences Pvt Ltd Company Information Table 19. Vyome Biosciences Pvt Ltd Business Overview Table 20. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolio Table 22. Vyome Biosciences Pvt Ltd Recent Developments Table 23. Viamet Pharmaceuticals Inc Company Information Table 24. Viamet Pharmaceuticals Inc Business Overview Table 25. Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio Table 27. Viamet Pharmaceuticals Inc Recent Developments Table 28. TGV-Laboratories Company Information Table 29. TGV-Laboratories Business Overview Table 30. TGV-Laboratories Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. TGV-Laboratories Dermatomycoses Drug Product Portfolio Table 32. TGV-Laboratories Recent Developments Table 33. Sol-Gel Technologies Ltd Company Information Table 34. Sol-Gel Technologies Ltd Business Overview Table 35. Sol-Gel Technologies Ltd Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolio Table 37. Sol-Gel Technologies Ltd Recent Developments Table 38. Novan Inc Company Information Table 39. Novan Inc Business Overview Table 40. Novan Inc Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Novan Inc Dermatomycoses Drug Product Portfolio Table 42. Novan Inc Recent Developments Table 43. Helix BioMedix Inc Company Information Table 44. Helix BioMedix Inc Business Overview Table 45. Helix BioMedix Inc Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Helix BioMedix Inc Dermatomycoses Drug Product Portfolio Table 47. Helix BioMedix Inc Recent Developments Table 48. Dermala Inc Company Information Table 49. Dermala Inc Business Overview Table 50. Dermala Inc Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Dermala Inc Dermatomycoses Drug Product Portfolio Table 52. Dermala Inc Recent Developments Table 53. Daewoong Pharmaceutical Co Ltd Company Information Table 54. Daewoong Pharmaceutical Co Ltd Business Overview Table 55. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolio Table 57. Daewoong Pharmaceutical Co Ltd Recent Developments Table 58. Blueberry Therapeutics Ltd Company Information Table 59. Blueberry Therapeutics Ltd Business Overview Table 60. Blueberry Therapeutics Ltd Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolio Table 62. Blueberry Therapeutics Ltd Recent Developments Table 63. Biolab Farmaceutica Ltda Company Information Table 64. Biolab Farmaceutica Ltda Business Overview Table 65. Biolab Farmaceutica Ltda Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolio Table 67. Biolab Farmaceutica Ltda Recent Developments Table 68. Anacor Pharmaceuticals Inc Company Information Table 69. Anacor Pharmaceuticals Inc Business Overview Table 70. Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio Table 72. Anacor Pharmaceuticals Inc Recent Developments Table 73. Global Dermatomycoses Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 74. Global Dermatomycoses Drug Sales by Region (2021-2026) & (W Units) Table 75. Global Dermatomycoses Drug Sales Market Share by Region (2021-2026) Table 76. Global Dermatomycoses Drug Sales by Region (2027-2032) & (W Units) Table 77. Global Dermatomycoses Drug Sales Market Share by Region (2027-2032) Table 78. Global Dermatomycoses Drug Revenue by Region (2021-2026) & (US$ Million) Table 79. Global Dermatomycoses Drug Revenue Market Share by Region (2021-2026) Table 80. Global Dermatomycoses Drug Revenue by Region (2027-2032) & (US$ Million) Table 81. Global Dermatomycoses Drug Revenue Market Share by Region (2027-2032) Table 82. North America Dermatomycoses Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. North America Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 84. North America Dermatomycoses Drug Sales by Country (2027-2032) & (W Units) Table 85. North America Dermatomycoses Drug Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Dermatomycoses Drug Revenue by Country (2027-2032) & (US$ Million) Table 87. Europe Dermatomycoses Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Europe Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 89. Europe Dermatomycoses Drug Sales by Country (2027-2032) & (W Units) Table 90. Europe Dermatomycoses Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. Europe Dermatomycoses Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. Asia Pacific Dermatomycoses Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Asia Pacific Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 94. Asia Pacific Dermatomycoses Drug Sales by Country (2027-2032) & (W Units) Table 95. Asia Pacific Dermatomycoses Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. Asia Pacific Dermatomycoses Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. South America Dermatomycoses Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. South America Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 99. South America Dermatomycoses Drug Sales by Country (2027-2032) & (W Units) Table 100. South America Dermatomycoses Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. South America Dermatomycoses Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. Middle East and Africa Dermatomycoses Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Middle East and Africa Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 104. Middle East and Africa Dermatomycoses Drug Sales by Country (2027-2032) & (W Units) Table 105. Middle East and Africa Dermatomycoses Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. Middle East and Africa Dermatomycoses Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. Global Dermatomycoses Drug Sales by Type (2021-2026) & (W Units) Table 108. Global Dermatomycoses Drug Sales by Type (2027-2032) & (W Units) Table 109. Global Dermatomycoses Drug Sales Market Share by Type (2021-2026) Table 110. Global Dermatomycoses Drug Sales Market Share by Type (2027-2032) Table 111. Global Dermatomycoses Drug Revenue by Type (2021-2026) & (US$ Million) Table 112. Global Dermatomycoses Drug Revenue by Type (2027-2032) & (US$ Million) Table 113. Global Dermatomycoses Drug Revenue Market Share by Type (2021-2026) Table 114. Global Dermatomycoses Drug Revenue Market Share by Type (2027-2032) Table 115. Global Dermatomycoses Drug Price by Type (2021-2026) & (US$/Unit) Table 116. Global Dermatomycoses Drug Price by Type (2027-2032) & (US$/Unit) Table 117. Global Dermatomycoses Drug Sales by Application (2021-2026) & (W Units) Table 118. Global Dermatomycoses Drug Sales by Application (2027-2032) & (W Units) Table 119. Global Dermatomycoses Drug Sales Market Share by Application (2021-2026) Table 120. Global Dermatomycoses Drug Sales Market Share by Application (2027-2032) Table 121. Global Dermatomycoses Drug Revenue by Application (2021-2026) & (US$ Million) Table 122. Global Dermatomycoses Drug Revenue by Application (2027-2032) & (US$ Million) Table 123. Global Dermatomycoses Drug Revenue Market Share by Application (2021-2026) Table 124. Global Dermatomycoses Drug Revenue Market Share by Application (2027-2032) Table 125. Global Dermatomycoses Drug Price by Application (2021-2026) & (US$/Unit) Table 126. Global Dermatomycoses Drug Price by Application (2027-2032) & (US$/Unit) Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Dermatomycoses Drug Distributors List Table 130. Dermatomycoses Drug Customers List Table 131. Dermatomycoses Drug Industry Trends Table 132. Dermatomycoses Drug Industry Drivers Table 133. Dermatomycoses Drug Industry Restraints Table 134. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Dermatomycoses Drug Product Image Figure 5. Global Dermatomycoses Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Dermatomycoses Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Dermatomycoses Drug Sales (2021-2032) & (W Units) Figure 8. Global Dermatomycoses Drug Average Price (US$/Unit) & (2021-2032) Figure 9. BB-2603 Product Image Figure 10. Dapaconazole Product Image Figure 11. Clotrimazole Product Image Figure 12. Others Product Image Figure 13. Hospital Product Image Figure 14. Clinic Product Image Figure 15. Others Product Image Figure 16. Global Dermatomycoses Drug Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Dermatomycoses Drug, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Dermatomycoses Drug Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Dermatomycoses Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Dermatomycoses Drug Sales by Region in 2025 Figure 22. Global Dermatomycoses Drug Revenue by Region in 2025 Figure 23. North America Dermatomycoses Drug Market Size by Country in 2025 Figure 24. North America Dermatomycoses Drug Sales Market Share by Country (2021-2032) Figure 25. North America Dermatomycoses Drug Revenue Market Share by Country (2021-2032) Figure 26. United States Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Dermatomycoses Drug Market Size by Country in 2025 Figure 30. Europe Dermatomycoses Drug Sales Market Share by Country (2021-2032) Figure 31. Europe Dermatomycoses Drug Revenue Market Share by Country (2021-2032) Figure 32. Germany Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Dermatomycoses Drug Market Size by Country in 2025 Figure 43. Asia Pacific Dermatomycoses Drug Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Dermatomycoses Drug Revenue Market Share by Country (2021-2032) Figure 45. China Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Dermatomycoses Drug Market Size by Country in 2025 Figure 54. South America Dermatomycoses Drug Sales Market Share by Country (2021-2032) Figure 55. South America Dermatomycoses Drug Revenue Market Share by Country (2021-2032) Figure 56. Brazil Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Dermatomycoses Drug Market Size by Country in 2025 Figure 60. Middle East and Africa Dermatomycoses Drug Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Dermatomycoses Drug Revenue Market Share by Country (2021-2032) Figure 62. Egypt Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Dermatomycoses Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Dermatomycoses Drug Sales Market Share by Type (2021-2032) Figure 68. Global Dermatomycoses Drug Revenue Market Share by Type (2021-2032) Figure 69. Global Dermatomycoses Drug Price (US$/Unit) by Type (2021-2032) Figure 70. Global Dermatomycoses Drug Sales Market Share by Application (2021-2032) Figure 71. Global Dermatomycoses Drug Revenue Market Share by Application (2021-2032) Figure 72. Global Dermatomycoses Drug Price (US$/Unit) by Application (2021-2032) Figure 73. Dermatomycoses Drug Value Chain Figure 74. Dermatomycoses Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Dermatomycoses Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • BB-2603
  • Dapaconazole
  • Clotrimazole
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Vyome Biosciences Pvt Ltd
  • Viamet Pharmaceuticals Inc
  • TGV-Laboratories
  • Sol-Gel Technologies Ltd
  • Novan Inc
  • Helix BioMedix Inc
  • Dermala Inc
  • Daewoong Pharmaceutical Co Ltd
  • Blueberry Therapeutics Ltd
  • Biolab Farmaceutica Ltda
  • Anacor Pharmaceuticals Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Dermatomycoses Drug Market Size (2021-2032)
  4. 2.2.2 Global Dermatomycoses Drug Sales (2021-2032)
  5. 2.2.3 Global Dermatomycoses Drug Market Average Price (2021-2032)
  6. 2.3 Dermatomycoses Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 BB-2603
  9. 2.3.3 Dapaconazole
  10. 2.3.4 Clotrimazole
  11. 2.3.5 Others
  12. 2.4 Dermatomycoses Drug by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Hospital
  15. 2.4.3 Clinic
  16. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Dermatomycoses Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Dermatomycoses Drug Sales (W Units) of Manufacturers (2021-2026)
  3. 3.3 Global Dermatomycoses Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Dermatomycoses Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Dermatomycoses Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Dermatomycoses Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Dermatomycoses Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Dermatomycoses Drug, Established Date
  9. 3.9 Global Dermatomycoses Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Vyome Biosciences Pvt Ltd
  2. 4.1.1 Vyome Biosciences Pvt Ltd Company Information
  3. 4.1.2 Vyome Biosciences Pvt Ltd Business Overview
  4. 4.1.3 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolio
  6. 4.1.5 Vyome Biosciences Pvt Ltd Recent Developments
  7. 4.2 Viamet Pharmaceuticals Inc
  8. 4.2.1 Viamet Pharmaceuticals Inc Company Information
  9. 4.2.2 Viamet Pharmaceuticals Inc Business Overview
  10. 4.2.3 Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
  12. 4.2.5 Viamet Pharmaceuticals Inc Recent Developments
  13. 4.3 TGV-Laboratories
  14. 4.3.1 TGV-Laboratories Company Information
  15. 4.3.2 TGV-Laboratories Business Overview
  16. 4.3.3 TGV-Laboratories Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 TGV-Laboratories Dermatomycoses Drug Product Portfolio
  18. 4.3.5 TGV-Laboratories Recent Developments
  19. 4.4 Sol-Gel Technologies Ltd
  20. 4.4.1 Sol-Gel Technologies Ltd Company Information
  21. 4.4.2 Sol-Gel Technologies Ltd Business Overview
  22. 4.4.3 Sol-Gel Technologies Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolio
  24. 4.4.5 Sol-Gel Technologies Ltd Recent Developments
  25. 4.5 Novan Inc
  26. 4.5.1 Novan Inc Company Information
  27. 4.5.2 Novan Inc Business Overview
  28. 4.5.3 Novan Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Novan Inc Dermatomycoses Drug Product Portfolio
  30. 4.5.5 Novan Inc Recent Developments
  31. 4.6 Helix BioMedix Inc
  32. 4.6.1 Helix BioMedix Inc Company Information
  33. 4.6.2 Helix BioMedix Inc Business Overview
  34. 4.6.3 Helix BioMedix Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Helix BioMedix Inc Dermatomycoses Drug Product Portfolio
  36. 4.6.5 Helix BioMedix Inc Recent Developments
  37. 4.7 Dermala Inc
  38. 4.7.1 Dermala Inc Company Information
  39. 4.7.2 Dermala Inc Business Overview
  40. 4.7.3 Dermala Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Dermala Inc Dermatomycoses Drug Product Portfolio
  42. 4.7.5 Dermala Inc Recent Developments
  43. 4.8 Daewoong Pharmaceutical Co Ltd
  44. 4.8.1 Daewoong Pharmaceutical Co Ltd Company Information
  45. 4.8.2 Daewoong Pharmaceutical Co Ltd Business Overview
  46. 4.8.3 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolio
  48. 4.8.5 Daewoong Pharmaceutical Co Ltd Recent Developments
  49. 4.9 Blueberry Therapeutics Ltd
  50. 4.9.1 Blueberry Therapeutics Ltd Company Information
  51. 4.9.2 Blueberry Therapeutics Ltd Business Overview
  52. 4.9.3 Blueberry Therapeutics Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolio
  54. 4.9.5 Blueberry Therapeutics Ltd Recent Developments
  55. 4.10 Biolab Farmaceutica Ltda
  56. 4.10.1 Biolab Farmaceutica Ltda Company Information
  57. 4.10.2 Biolab Farmaceutica Ltda Business Overview
  58. 4.10.3 Biolab Farmaceutica Ltda Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolio
  60. 4.10.5 Biolab Farmaceutica Ltda Recent Developments
  61. 4.11 Anacor Pharmaceuticals Inc
  62. 4.11.1 Anacor Pharmaceuticals Inc Company Information
  63. 4.11.2 Anacor Pharmaceuticals Inc Business Overview
  64. 4.11.3 Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
  66. 4.11.5 Anacor Pharmaceuticals Inc Recent Developments
5 Global Dermatomycoses Drug Market Scenario by Region
  1. 5.1 Global Dermatomycoses Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Dermatomycoses Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Dermatomycoses Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Dermatomycoses Drug Sales by Region: 2027-2032
  5. 5.3 Global Dermatomycoses Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Dermatomycoses Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Dermatomycoses Drug Revenue by Region: 2027-2032
  8. 5.4 North America Dermatomycoses Drug Market Facts & Figures by Country
  9. 5.4.1 North America Dermatomycoses Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Dermatomycoses Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Dermatomycoses Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Dermatomycoses Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Dermatomycoses Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Dermatomycoses Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Dermatomycoses Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Dermatomycoses Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Dermatomycoses Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Dermatomycoses Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Dermatomycoses Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Dermatomycoses Drug Market Facts & Figures by Country
  41. 5.7.1 South America Dermatomycoses Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Dermatomycoses Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Dermatomycoses Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Dermatomycoses Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Dermatomycoses Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Dermatomycoses Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Dermatomycoses Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Dermatomycoses Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Dermatomycoses Drug Sales by Type (2021-2032) & (W Units)
  3. 6.1.2 Global Dermatomycoses Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Dermatomycoses Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Dermatomycoses Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Dermatomycoses Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Dermatomycoses Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Dermatomycoses Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Dermatomycoses Drug Sales by Application (2021-2032) & (W Units)
  3. 7.1.2 Global Dermatomycoses Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Dermatomycoses Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Dermatomycoses Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Dermatomycoses Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Dermatomycoses Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Dermatomycoses Drug Value Chain Analysis
  2. 8.1.1 Dermatomycoses Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Dermatomycoses Drug Production Mode & Process
  5. 8.2 Dermatomycoses Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Dermatomycoses Drug Distributors
  8. 8.2.3 Dermatomycoses Drug Customers
9 Global Dermatomycoses Drug Analyzing Market Dynamics
  1. 9.1 Dermatomycoses Drug Industry Trends
  2. 9.2 Dermatomycoses Drug Industry Drivers
  3. 9.3 Dermatomycoses Drug Industry Opportunities and Challenges
  4. 9.4 Dermatomycoses Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst